Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Novo Nordisk to Acquire Emisphere Technologies | Contract Pharma

What are you searching for?

Sign in
Breaking News

Novo Nordisk to Acquire Emisphere Technologies

Gains the Eligen SNAC oral delivery technology.

By: Contract Pharma

Contract Pharma Staff

Novo Nordisk entered into a definitive agreement to acquire Emisphere Technologies Inc., a drug delivery company, for $1.35 billion. The company’s proprietary technologies, such as the Eligen SNAC technology, enable oral formulations of therapeutics.

The companies have collaborated since 2007 and Emisphere’s drug delivery technology Eligen SNAC is used by Novo Nordisk under an existing licence agreement in the oral formulation of Novo Nordisk’s GLP-1 receptor agonist semaglutide, sold under the brand name Rybelsus.

As part of the transaction, Novo Nordisk will also acquire related Eligen SNAC royalty stream obligations owed to MHR Fund Management LLC, the largest shareholder of Emisphere, for $450 million.

With these acquisitions, Novo Nordisk eliminates its future royalty obligations to Emisphere and MHR and obtains full access to the Eligen SNAC technology platform thereby enabling Novo Nordisk to expand the portfolio of oral biologic pipeline assets across therapy areas.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics